Phase 1 Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are generally in good health, as confirmed by a medical assessment (re-screening is allowed if needed).
- You score 24 or higher on a standard memory and thinking test called the Montreal Cognitive Assessment.
- Any regular medications you take have been at a stable dose for at least 8 weeks before the study drug is given, and your doctor expects this to stay the same for at least 6 months.
For the multiple-dose part of the trial only:
- You have been diagnosed with Parkinson's disease using a specific set of recognised medical guidelines.
- Your Parkinson's disease is at a relatively early to mid stage (Stage 1 to 2.5 on a standard scale, measured when medication is not active).
- A specialised spinal fluid test for a Parkinson's-related protein has come back positive — a recent positive result from within the last year may also be accepted with approval (US and Japan only).
- Your sense of smell scores at or below the 20th percentile for your age and sex on a standard smell test (EU and UK only).
- A specific brain scan has shown results consistent with Parkinson's disease.
- If you are not currently taking Parkinson's disease medication, your doctor does not expect you to need to start within 6 months.
- Your body weight is between 40 kg (88 lbs) and 110 kg (242 lbs), and your body mass index (BMI) is between 17 and 34.
Who may not be able to join:
- You have a significant neurological condition affecting the brain or nervous system other than Parkinson's disease (multiple-dose part only).
- You have a current serious or unstable illness affecting the heart, liver, kidneys, digestive system, lungs, hormones, nervous system, mental health, immune system, or blood that could affect your safety or the study results.
- You are generally frail, or have a condition that could make study procedures unsafe — for example, a serious spinal problem, a bleeding disorder, low platelet counts, or raised pressure in the skull.
- You have an abnormal heart tracing (ECG) at the screening stage that your doctor believes could increase risks or affect test results.
- You are currently receiving Parkinson's disease medication delivered continuously through the intestine (for example, a treatment called Duodopa) (multiple-dose part only).
- Your kidneys are not working well enough, based on a specific blood test result (multiple-dose part only) (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Travis Lewis, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company
Phone: 917-336-9310
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Serious Adverse Events (SAEs); Incidence of Treatment Emergent Adverse Events (TEAEs); Number of discontinuations due to Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.